Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Evangelos N. Liberopoulos"'
Autor:
George S. Stergiou, Angeliki Ntineri, Ariadni Menti, Natasa Kalpourtzi, Charalambos Vlachopoulos, Evangelos N. Liberopoulos, Loukianos Rallidis, Dimitris Richter, Magda Gavana, Apostolos Vantarakis, Grigoris Chlouverakis, Christos Hajichristodoulou, Grigoris Trypsianis, Paraskevi V. Voulgari, Yannis Alamanos, Argiro Karakosta, Giota Touloumi
Publikováno v:
Hellenic Journal of Cardiology, Vol 69, Iss , Pp 1-8 (2023)
Background: Greece was recently reclassified from low- to medium-risk country in terms of cardiovascular disease, with 27% of cardiovascular deaths attributed to hypercholesterolemia. EMENO nationwide survey (2013-2016) assessed the epidemiology of d
Externí odkaz:
https://doaj.org/article/fb810b7ef0d646ed8b466f5f687b3c2f
Publikováno v:
Healthcare, Vol 11, Iss 9, p 1310 (2023)
Obesity is a chronic disease and a major public health problem due to its association with non-communicable diseases and all-cause mortality. An increased energy intake and decreased physical activity have been long recognized as the classical parame
Externí odkaz:
https://doaj.org/article/c5e9cc88cc9248cf86a6b912f9e6f089
Autor:
Loukianos S. Rallidis, Ioannis Skoumas, Evangelos N. Liberopoulos, Charalambos Vlachopoulos, Estela Kiouri, Iosif Koutagiar, Georgia Anastasiou, Nikolaos Kosmas, Moses S. Elisaf, Dimitrios Tousoulis, Efstathios Iliodromitis
Publikováno v:
Hellenic Journal of Cardiology, Vol 61, Iss 4, Pp 241-245 (2020)
Background: In randomized clinical trials, proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) effectively reduce low-density lipoprotein-cholesterol (LDL-C) with a favorable tolerability and safety profile. Our purpose is to provide re
Externí odkaz:
https://doaj.org/article/3b9b21ac806d4147aeba29388eb1a6c1
Autor:
Christos V. Rizos, Matilda Florentin, Ioannis Skoumas, Konstantinos Tziomalos, Loukianos Rallidis, Vasileios Kotsis, Vasileios Athyros, Emmanouil Skalidis, Genovefa Kolovou, Anastasia Garoufi, Eleni Bilianou, Iosif Koutagiar, Dimitrios Agapakis, Estela Kiouri, Christina Antza, Niki Katsiki, Evangelos Zacharis, Achilleas Attilakos, George Sfikas, Panagiotis Anagnostis, Demosthenes B. Panagiotakos, Evangelos N. Liberopoulos
Publikováno v:
Lipids in Health and Disease, Vol 19, Iss 1, Pp 1-13 (2020)
Abstract Background Familial hypercholesterolemia (FH) is characterized by elevated low-density lipoprotein cholesterol (LDL-C) levels and increased cardiovascular disease (CVD) risk. FH patients often have increased lipoprotein(a) [Lp(a)] levels, wh
Externí odkaz:
https://doaj.org/article/aecf23dc5acf458896d849d0d3514472
Autor:
Stefania E. Makariou, Moses Elisaf, Anna Challa, Constantinos C. Tellis, Alexandros D. Tselepis, Evangelos N. Liberopoulos
Publikováno v:
Journal of Nutrition & Intermediary Metabolism, Vol 16, Iss , Pp - (2019)
Background: Patients with metabolic syndrome (MetS) have low serum 25-hydroxyvitamin D (25(OH)VitD) levels. Low 25(OH)VitD has been associated with several emerging cardiovascular disease (CVD) risk factors, while VitD administration may ameliorate t
Externí odkaz:
https://doaj.org/article/2028fa89bd494b6e8000c1f0beddbe21
Publikováno v:
Therapeutic Advances in Endocrinology and Metabolism, Vol 6 (2015)
Dapagliflozin is a selective and reversible inhibitor of sodium–glucose linked transporter type 2 (SGLT2), which mediates approximately 90% of active renal glucose reabsorption in the early proximal tubule of the kidney. Dapagliflozin significantly
Externí odkaz:
https://doaj.org/article/4b9b346c5aab4092a4a78da1f6e57e91
Autor:
Theocharis Koufakis, Evangelos N. Liberopoulos, Alexander Kokkinos, Pantelis Zebekakis, Kalliopi Kotsa
Publikováno v:
Drugs. 83:469-477
Publikováno v:
American Journal of Cardiovascular Drugs. 22:357-361
Current guidelines for the management of hyperglycemia recommend the use of agents with proven cardiovascular (CV) benefit in patients with type 2 diabetes (T2D) and established CV disease. Although both glucagon-like peptide 1 receptor agonists (GLP
Autor:
Panagiotis Anagnostis, Christos V. Rizos, Ioannis Skoumas, Loukianos Rallidis, Konstantinos Tziomalos, Emmanuel Skalidis, Vasileios Kotsis, Michalis Doumas, Genovefa Kolovou, George Sfikas, Anastasia Garoufi, Vaia Lambadiari, Ioanna Dima, Estela Kiouri, Dimitrios Agapakis, Evangelos Zacharis, Christina Antza, Vana Kolovou, Charalambos Koumaras, George Bantouvakis, George Liamis, Evangelos N. Liberopoulos
Publikováno v:
Atherosclerosis. 355:25
Lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD) in the general population. However, such a role in patients with familial hypercholesterolemia (FH) is less documented. The purpose of this study
Autor:
Vassilios G, Athyros, Emmanouel, Ganotakis, Genovefa D, Kolovou, Vassilios, Nicolaou, Apostolos, Achimastos, Eleni, Bilianou, Theodore, Alexandrides, Asterios, Karagiannis, Konstantinos, Paletas, Evangelos N, Liberopoulos, Konstantinos, Tziomalos, Dimitrios, Petridis, Anna, Kakafika, Moses S, Elisaf, Dimitri P, Mikhailidis, N, Tsakoudakis
Publikováno v:
Current Vascular Pharmacology. 9:647-657
AIM: To assess the reduction in estimated cardiovascular disease (e-CVD) risk after multifactorial treatment for 6 months and follow this change during the next 3-years. PATIENTS-METHODS: This prospective, randomized, target driven study included 1,1